Timothy Kalmer
Family · Milwaukee, WINPI 1316320724
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,393, 2.1 times the $669 reported in 2021. Among family clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$824
- Johnson & Johnson$812
- AbbVie$664
- Teva Pharmaceuticals USA, Inc.$567
- Lundbeck LLC$529
- Neurocrine Biosciences, Inc.$397
- plus $1K from 9 others
What the payments were for
- Food & beverage$4,84995%
- Education$2365%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 41 | $824 |
| Johnson & Johnson | 44 | $812 |
| AbbVie | 42 | $664 |
| Teva Pharmaceuticals USA, Inc. | 25 | $567 |
| Lundbeck LLC | 28 | $529 |
| Neurocrine Biosciences, Inc. | 16 | $397 |
| Otsuka America Pharmaceutical, Inc. | 16 | $302 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $250 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $212 |
| Sunovion Pharmaceuticals Inc. | 8 | $143 |
| Indivior Inc. | 7 | $140 |
| Vanda Pharmaceuticals Inc. | 6 | $131 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| Noven Therapeutics, LLC | 2 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$132
- INVEGA SUSTENNA$125
- INVEGA TRINZA$125
- INGREZZA$125
How this compares
$5,085 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 123 | $398,399 |
| Invega TrinzaPaliperidone Palmitate | 40 | $357,392 |
| IngrezzaValbenazine Tosylate | 44 | $345,463 |
| Abilify MaintenaAripiprazole | 87 | $237,204 |
| Invega HafyeraPaliperidone Palmitate | 12 | $218,003 |
| AristadaAripiprazole Lauroxil | 42 | $134,066 |
| VraylarCariprazine Hcl | 61 | $87,708 |
| LybalviOlanzapine/Samidorphan Malate | 43 | $66,077 |
| Risperdal ConstaRisperidone Microspheres | 54 | $62,177 |
| RexultiBrexpiprazole | 28 | $45,227 |
| Risperidone ErRisperidone Microspheres | 28 | $40,998 |
| TrintellixVortioxetine Hydrobromide | 77 | $38,573 |
| VivitrolNaltrexone Microspheres | 13 | $21,997 |
| Aripiprazole | 160 | $21,074 |
| Asenapine Maleate | 11 | $16,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $812 | $817,968217 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $397 | $345,46344 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $302 | $282,431115 claims |
| Alkermes, Inc.Aristada, Lybalvi, Vivitrol | $824 | $222,14098 claims |
| AbbVieVraylar | $664 | $87,70861 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $212 | $38,57377 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $567 | $2,75661 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.
Other family in Milwaukee
- Stephanie OffordMilwaukee$116K
- Tracy NelsonMilwaukee$24K
- Sarah EmmerichMilwaukee$15K
- Erin LassanskeMilwaukee$14K
- Katrina BaxterMilwaukee$13K
- Natalie KerberMilwaukee$12K
- Jenta AlexanderMilwaukee$12K
- Lileta WintMilwaukee$10K
- Mary Jane de JesusMilwaukee$10K
- Kelley BeltranMilwaukee$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.